Crinetics Pharmaceuticals (CRNX) Deferred Taxes (2017 - 2018)
Crinetics Pharmaceuticals' (CRNX) quarterly Deferred Taxes came in at -$374000.0 in Q4 2018, down 12566.67% year-on-year from N/an in Q4 2017, and down 1110.81% quarter-over-quarter from $37000.0 in Q3 2018.
Crinetics Pharmaceuticals (CRNX) Deferred Taxes (2017 - 2018) Analysis & Trends
Crinetics Pharmaceuticals' Deferred Taxes history runs 2 years deep, the most recent figure standing at -$374000.0 for Q4 2018.
- On a quarterly basis, Deferred Taxes fell 12566.67% year-over-year to -$374000.0 in Q4 2018; TTM through Dec 2018 was -$332000.0, a N/A change from a year earlier, with the FY2018 full-year figure at -$261000.0, down 1840.0% from the prior year.
- Deferred Taxes fell to -$374000.0 in Q4 2018 per CRNX's latest filing, from $37000.0 in the prior quarter.
- Across five years, Deferred Taxes topped out at $37000.0 in Q3 2018 and bottomed at -$374000.0 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,741.39 Bn | 66,741.11 Bn | - | - |
| 2 | Nanobiotix | 1,912.31 Bn | 1,912.25 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | -859,000.00 |
| 4 | BeOne Medicines | 467.15 Bn | 462.36 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 123.00 Bn | 115.76 Bn | 2.59 Bn | -65.30 Mn |
| 6 | Regeneron Pharmaceuticals | 70.22 Bn | 61.47 Bn | 3.31 Bn | 96.00 Mn |
| 7 | Belite Bio | 62.93 Bn | 62.93 Bn | - | - |
| 8 | Argenx Se | 55.76 Bn | 50.57 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.70 Bn | 34.69 Bn | 959.66 Mn | 9.31 Mn |
| 10 | Crinetics Pharmaceuticals | 8.73 Bn | 7.44 Bn | 10.53 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | -374,000.00 |
| Sep 30, 2018 | 37,000.00 |
| Dec 31, 2017 | 3,000.00 |
| Sep 30, 2017 | 2,000.00 |